Come up with a name for your new list and we'll add to it:
Lonza Group - Cutanogen Corporation raised a round of funding on November 18, 2014. Investors include
Amarantus Bioscience Holdings.
Cutanogen Corporation is a subsidiary of Lonza which is developing Engineered Skin Substitute (ESS), an autologous skin replacement product for the treatment of Stage 3 and Stage 4 intractable severe …